<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01951066</url>
  </required_header>
  <id_info>
    <org_study_id>DMEO-001</org_study_id>
    <nct_id>NCT01951066</nct_id>
  </id_info>
  <brief_title>Diabetic Macular Edema Treated With Ozurdex (DMEO)</brief_title>
  <acronym>DMEO</acronym>
  <official_title>Diabetic Macular Edema Treated With Ozurdex (DMEO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure various pro-permeability factors in the aqueous humor of patients with
      persistent/recurrent diabetic macular edema
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Diabetic Macular Edema (DME) are increasingly being treated with molecules
      targeting vascular endothelial factor (VEGF). One potential advantage of a dexamethasone
      implant over specific VEGF antagonists is that steroids suppress production of multiple
      pro-permeability factors.

      Our primary objective is to measure the pro-permeability factors in the aqueous humor of
      patients with persistent/recurrent macular edema despite prior treatment with anti-VEGF
      agents at baseline and at 1, 2, 3, and 4 months after intraocular injection of a
      dexamethasone implant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent</measure>
    <time_frame>1, 2, 3, and 4 months after injection of a dexamethasone implant or anti-VEGF agent</time_frame>
    <description>Changes in propermeability factor levels were correlated with changes in edema using the person correlation coefficient (this was calculated using data from all time points).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Group 1 (dexamethasone implant/anti-VEGF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in group 1 received an injection of an dexamethasone implant at baseline followed by PRN anti-VEGF injections after crossover at week 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (anti-VEGF/dexamethasone implant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in group 2 received prn anti-VEGF injections followed by injection of a dexamethasone implant after crossover at week 16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Implant</intervention_name>
    <description>Patients will receive a single injection of a dexmethasone implant</description>
    <arm_group_label>Group 1 (dexamethasone implant/anti-VEGF)</arm_group_label>
    <arm_group_label>Group 2 (anti-VEGF/dexamethasone implant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF injection</intervention_name>
    <description>Patients will receive PRN injections of an anti-VEGF agent</description>
    <arm_group_label>Group 1 (dexamethasone implant/anti-VEGF)</arm_group_label>
    <arm_group_label>Group 2 (anti-VEGF/dexamethasone implant)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Signed informed consent and authorization of use and disclosure of protected health
             information

               -  Age more than or equal to 18 years

               -  Diagnosis of diabetic macular edema

               -  Intraretinal or subretinal fluid in the macula determined by Spectralis OCT

               -  Best corrected visual acuity score in the study eye of 20/30 to 20/400 inclusive
                  (Snellen equivalents using the ETDRS protocol at a distance of 4 meters)

               -  In the opinion of the investigator, decreased vision in the study eye is due to
                  foveal thickening from DME and not from other obvious causes of decreased vision

               -  Persistent or recurrent edema despite prolonged treatment with an anti-VEFG agent

        Exclusion Criteria:

          -  • Scatter laser photocoagulation or macular photocoagulation within 3 months of study
             entry in the study eye

               -  Intraocular surgery in the study eye within 3 months of study entry

               -  Use of intraocular or periocular injection of steroids in the study eye (e.g.,
                  triamcinolone) within 4 months of study entry

               -  Previous use of an anti-VEGF drug within 1 month of study entry

               -  Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within 1 month of study entry

               -  Any condition that the investigator believes would pose a significant hazard to
                  the subject if investigational therapy were initiated.

               -  Inability to comply with study or follow up procedures

               -  History of glaucoma. (Patients who have undergone filtration surgery may be
                  included)

               -  Patients with active or suspected ocular or periocular infection, including most
                  viral diseases of the cornea and conjunctiva, including active epithelial herpes
                  simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial
                  infections, and fungal diseases.

               -  Aphakic eyes with rupture of the posterior lens capsule.

               -  Eyes with ACIOL and rupture of the posterior lens capsule.

               -  Patients with hypersensitivity to dexamethasone or to any other components of the
                  product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Campochiaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2013</study_first_posted>
  <results_first_submitted>May 10, 2016</results_first_submitted>
  <results_first_submitted_qc>June 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2016</results_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Peter A Campochiaro, MD</investigator_full_name>
    <investigator_title>Professor of Ophthalmology and Neuroscience</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (Dexamethasone Implant/Anti-VEGF)</title>
          <description>Patients in group 1 received an injection of an dexamethasone implant at baseline followed by PRN anti-VEGF injections after crossover at week 16.
Dexamethasone Implant: Patients will receive a single injection of a dexmethasone implant
Anti-VEGF injection: Patients will receive PRN injections of an anti-VEGF agent</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (Anti-VEGF/Dexamethasone Implant)</title>
          <description>Patients in group 2 received prn anti-VEGF injections followed by injection of a dexamethasone implant after crossover at week 16.
Dexamethasone Implant: Patients will receive a single injection of a dexmethasone implant
Anti-VEGF injection: Patients will receive PRN injections of an anti-VEGF agent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (Baseline to Week 16)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (Week 16 to Week 32)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" lower_limit="47" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Intraretinal Fluid</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Disease Duration</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" lower_limit="3" upper_limit="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Anti-VEGF injections</title>
          <units>Injections</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" lower_limit="0" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Intraocular Steroids</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Laser</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grid Laser</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scatter Laser Photocoagulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Best Corrected Visual Acuity</title>
          <description>The Best Corrected Visual Acuity (BCVA) was measured using the Early Treatment of Diabetic Retinopathy Study (ETDRS) Score. Patient can have an ETDRS score ranging from 5 to 100. A higher ETDRS Score represents better visual acuity.</description>
          <units>ETDRS Score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" lower_limit="30" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Central Subfield Thickness</title>
          <description>The Central Subfield Thickness (CST) was measured using Spectralis OCT machine.</description>
          <units>Microns</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="464.3" lower_limit="280" upper_limit="779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent</title>
        <description>Changes in propermeability factor levels were correlated with changes in edema using the person correlation coefficient (this was calculated using data from all time points).</description>
        <time_frame>1, 2, 3, and 4 months after injection of a dexamethasone implant or anti-VEGF agent</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone Implant</title>
            <description>Patients received an injection of an dexamethasone implant</description>
          </group>
          <group group_id="O2">
            <title>Anti-VEGF Agent</title>
            <description>Patients received PRN injections of an Anti-VEGF agent</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent</title>
          <description>Changes in propermeability factor levels were correlated with changes in edema using the person correlation coefficient (this was calculated using data from all time points).</description>
          <units>Pearson correlation coefficient (r)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGF-BP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47"/>
                    <measurement group_id="O2" value="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45"/>
                    <measurement group_id="O2" value="0.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45"/>
                    <measurement group_id="O2" value="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EG-VEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43"/>
                    <measurement group_id="O2" value="-0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endostatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41"/>
                    <measurement group_id="O2" value="0.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiopoietin-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40"/>
                    <measurement group_id="O2" value="0.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF-BP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36"/>
                    <measurement group_id="O2" value="0.435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persephin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35"/>
                    <measurement group_id="O2" value="0.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34"/>
                    <measurement group_id="O2" value="-0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>THSP-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33"/>
                    <measurement group_id="O2" value="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31"/>
                    <measurement group_id="O2" value="0.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30"/>
                    <measurement group_id="O2" value="-0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXCL16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29"/>
                    <measurement group_id="O2" value="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mitral valve repair surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency room visit because of a possible seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood transfusion due to severe anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Racing of heart</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Increased Intraocular pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eye soreness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bruising of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Patient had a fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Steroid injection in the hip due to arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Foot Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>[Peter A. Campochiaro</name_or_title>
      <organization>Wilmer Eye Institute, Johns Hopkins University School of Medicine</organization>
      <phone>(410) 955-5106</phone>
      <email>pcampo@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

